Kane Biotech Inc. · TSXV:KNE
Kane Biotech — Investor Presentation (April 2025)
14 slides from Kane Biotech's investor presentation, April 2025
Slide 1: Corporate Presentation
Corporate Presentation T S X - V: K N E OTC Markets : K N B I F APRIL 2025
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains forward-looking statements, which are made pursuant to the safe harbour provisions of the U.S. Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties which could cause the Company's
Slide 3: Kane Biotech: Developing novel wound care treatments that disrupt biofilms
Kane Biotech: Developing novel wound care treatments that disrupt biofilms and transform healing outcomes Focused on revyveTM 3
Slide 4: The Biofilm Problem
The Biofilm Problem Biofilm impaired healing is the largest unresolved problem in Biofilms are formed by a glue-like substance excreted by bacteria that… Wound Care The Centers for Disease Control and Prevention • protect and allow bacteria to survive and thrive in hostile environments. (CDC) has id
Slide 5: The Problem of Chronic Wounds
The Problem of Chronic Wounds • 10.5 million Medicare beneficiaries suffer from chronic, non-healing wounds 1 • The healing of a chronic wound is dependent on treating infections involving biofilms 2-4 • The most common bacteria observed in chronic wound infections 2,3 o S. aureus (in 93.5 % of the
Slide 6: revyve hydrogel dressing: treats bacteria and biofilms
✅Treats both bacteria and biofilms over 7 days ✅US FDA 510(k) cleared. Reimbursed by Medicare - Medicaid ✅Health Canada approved The hydrogel dressing market in the U.S. is estimated at USD $200 million in 2022 1 1. MRG Insights. Source: US and Global Wound Dressing Data 2022 6
Slide 7: revyve: Case Study A
revyveTM: Case Study A Wound healing and new tissue formation in right great toe was evident in 15 days of revyveTM wound gel use. 1. Le et al. Diagnostic Accuracy of Point-of-Care Fluorescence Imaging for the Detection of Bacterial Burden in Wounds: Results from the 350-Patient Fluorescence Imaging
Slide 8: revyve: Case Study B
revyveTM: Case Study B A 62 year-old woman with diabetes, obesity and chronic fibrotic phlebolymphedema of her lower limbs suffered from recurring venous ulcers on her legs over the last 20 years. Day 0 Day 35 Day 60 Outcomes The patient had a complete resolution of wound pain after 6 weeks. It was
Slide 9: Commercializing with a Pipeline
Commercializing with a Pipeline FDA approved 3 Pipeline of new products 2 Health Canada approval anticipated 1 Proven technology FDA Approval 2026 FDA Approval 2026 WOUND CLEANSER 9
Slide 10: Using Distributors to Bring revyve to Patients
Using Distributors to Bring 1 Signed agreements in UAE and Qatar. Saudi Arabia, Kuwait, Oman, Bahrain pending. Regulatory approvals pending revyveTM to Patients Regulatory Approval: 1 Anticipated 2025 10
Slide 11: revyve for Wound Care, Diabetes, Burn and Incisions
revyveTM for Wound Care, Diabetes, Burn and Incisions Product Regulatory Status Opportunity US FDA 510(k) cleared Chronic wounds, burns, diabetic revyve Antimicrobial Wound Gel Health Canada approved ulcerations US FDA 510(k) cleared Strong appeal in burns, battlefield revyve Antimicrobial Wound Gel
Slide 12: Team Summary
Summary Team Demonstrated activity against bacteria and biofilms • Robert Huizinga, PhD RN o Interim Chief Executive Officer Portfolio of patents • Ray Dupuis, CGA, MBA o Chief Financial Officer Approved in both US and Canada • Lori Christofalos, BSc. o Chief Quality Officer Pipeline of new
Slide 13: Share Summary
Share Summary Listing: TSX-V:KNE, OTC:KNBIF Contact Information: 52 Week Range: $0.09-0.16 Market Cap: $15M Dr. Robert Huizinga, Interim CEO Shares Outstanding: 154.8M rhuizinga@kanebiotech.com Ownership: Renaud Family 19.9%; Philip Renaud 16.4%; Insiders 1.4% C:(780) 970-1100 Ray Dupuis, Chief Fina
Slide 14: Corporate Presentation
Corporate Presentation T S X - V: K N E OTC Markets : K N B I F APRIL 2025